Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma

• Published in: Nutrition and cancer 2015, Vol.67 (7), p.1120-1130
• Main Authors: Zigmont, Victoria, Garrett, Amy, Peng, Jin, Seweryn, Michal, Rempala, Grzegorz A, Harris, Randall, Holloman, Christopher, Gundersen, Thomas E, Ahlbom, Anders, Feychting, Maria, Johannesen, Tom Borge, Grimsrud, Tom Kristian, Schwartzbaum, Judith
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Aged; blood serum; Brain cancer; Case-Control Studies; Central Nervous System Neoplasms - blood; Central Nervous System Neoplasms - diagnosis; Central Nervous System Neoplasms - pathology; confidence interval; Female; Glioma - blood; Glioma - diagnosis; Glioma - pathology; Humans; Janus; liquid chromatography; Male; mass spectrometry; Medical diagnosis; Medicin och hälsovetenskap; men; Mens health; Middle Aged; Norway; odds ratio; regression analysis; risk; Sex Factors; Vitamin D; Vitamin D - analogs & derivatives; Vitamin D - blood; Young Adult
• ISSN: 1532-7914; 0163-5581; 1532-7914
• DOI: 10.1080/01635581.2015.1073757

There are no previous studies of the association between prediagnostic serum vitamin D concentration and glioma. Vitamin D has immunosuppressive properties; as does glioma. It was, therefore, our hypothesis that elevated vitamin D concentration would increase glioma risk. We conducted a nested case-control study using specimens from the Janus Serum Bank cohort in Norway. Blood donors who were subsequently diagnosed with glioma (n = 592), between 1974 and 2007, were matched to donors without glioma (n = 1112) on date and age at blood collection and sex. We measured 25-hydroxyvitamin D [25(OH)D], an indicator of vitamin D availability, using liquid chromatography coupled with mass spectrometry. Seasonally adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated for each control quintile of 25(OH)D using conditional logistic regression. Among men diagnosed with high grade glioma >56, we found a negative trend (P = .04). Men diagnosed ≤ 56 showed a borderline positive trend (P = .08). High levels (>66 nmol/L) of 25(OH)D in men >56 were inversely related to high grade glioma from ≥2 yr before diagnosis (OR = 0.59; 95% CI = 0.38, 0.91) to ≥15 yr before diagnosis (OR = 0.61; 95% CI = 0.38,0.96). Our findings are consistent long before glioma diagnosis and are therefore unlikely to reflect preclinical disease.